Jazz Pharmaceuticals shared a post on LinkedIn:
“HER2 is an oncogenic driver across a range of malignancies, including breast, gastrointestinal, lung and other cancers. This widespread presence makes it an important target for the future of precision therapies.
Robert Iannone, Executive Vice President, Global Head of R/D and Chief Medical Officer, details a recent shift in oncology research and development, and why understanding a cancer’s unique genetic and biological makeup is now more critical than ever.”
Other articles about Jazz Pharmaceuticals on OncoDaily.